Recommendation for the use of Dexamethasone for the Treatment of Severe COVID-19

Recommendation for the use of Dexamethasone for the Treatment of Severe COVID-19

Recommendation for the use of Dexamethasone for the Treatment of Severe COVID-19

On 19 June 2020, the National Department of Health released a statement titled, Follow up statement on Dexamethasone by the Minister of Health. The statement summarised the outcomes of the Randomised Evaluation of COVID-19 therapy (RECOVER) Trial, which reported benefit from the use of Dexamethasone in the patients with severe COVID-19.

Based on the available results of the RECOVERY Trial, Dexamethasone is recommended in COVID-19 patients who require respiratory support only (i.e. those requiring ventilation or other forms of oxygen therapy). In the RECOVERY Trial, prednisone 40mg daily was used in women who were pregnant or breastfeeding.

 

Type
Guides/Guidelines
Topic
Communicable Diseases
Communicable Diseases, Primary Health Care
Language
English
Publisher
National Department of Health
Year
2020